Fujian Haixi Pharmaceuticals' (HKG:2637) HX9428 was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA).
The FTD was for the development of a treatment for neovascular age-related macular degeneration (nAMD), according to a Monday Hong Kong bourse filing.
The grant of the FTD will allow closer communication between the company and the regulator on the drug's clinical development.